Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Receivables - Net: 2020-2024

Historic Receivables - Net for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $38.5 million.

  • Maravai Lifesciences Holdings' Receivables - Net fell 21.71% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 21.71%. This contributed to the annual value of $38.5 million for FY2024, which is 29.46% down from last year.
  • According to the latest figures from FY2024, Maravai Lifesciences Holdings' Receivables - Net is $38.5 million, which was down 29.46% from $54.6 million recorded in FY2023.
  • Maravai Lifesciences Holdings' 5-year Receivables - Net high stood at $138.6 million for FY2022, and its period low was $38.5 million during FY2024.
  • Its 3-year average for Receivables - Net is $77.2 million, with a median of $54.6 million in 2023.
  • In the last 5 years, Maravai Lifesciences Holdings' Receivables - Net skyrocketed by 130.33% in 2021 and then tumbled by 60.61% in 2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Receivables - Net (Yearly) stood at $51.0 million in 2020, then soared by 130.33% to $117.5 million in 2021, then rose by 17.97% to $138.6 million in 2022, then tumbled by 60.61% to $54.6 million in 2023, then decreased by 29.46% to $38.5 million in 2024.